Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia XLH

The FDA Orphan Drug Designation provides significant advantages to investors by granting Anzor Pharmaceuticals valuable development incentives, regulatory support, and seven years of market exclusivity upon approval for its FGF23 peptide antagonist targeting XLH.

United States, 24th Jul 2025– Anzor Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead investigational therapy, a novel FGF23 peptide antagonist, for the treatment of X-linked hypophosphatemia (XLH), a rare and debilitating genetic disorder.

XLH is a serious, lifelong disease affecting approximately 1 in 20,000 individuals, characterized by excessive phosphate excretion, rickets, osteomalacia, poor bone development, dental problems, and significant morbidity in both children and adults. The disorder results from excess activity of the hormone fibroblast growth factor 23 (FGF23), leading to chronic hypophosphatemia and its downstream effects.

The FGF23 peptide antagonist being developed by Anzor Pharmaceuticals aims to selectively block the excessive activity of FGF23. Preclinical data indicate that antagonizing FGF23 can normalize phosphate homeostasis, improve bone integrity, and provide a targeted therapy with an improved safety profile compared to current options. This approach directly targets the disease mechanism rather than only addressing symptoms.

Orphan Drug Designation by the FDA is granted to drugs and biologics intended for the safe and effective treatment, diagnosis, or prevention of rare diseases affecting fewer than 200,000 people in the United States. This status provides important incentives for Anzor Pharmaceuticals, including tax credits for clinical testing, relief from certain FDA fees, and, if approved, seven years of marketing exclusivity for the FGF23 peptide antagonist in XLH.

“Receiving Orphan Drug Designation from the FDA is a significant milestone that advances our commitment to patients and families affected by XLH,” said a spokesperson for Anzor Pharmaceuticals. “We look forward to accelerating the clinical development of our FGF23 peptide antagonist and driving innovation for this underserved community.”

XLH represents a significant unmet medical need, with limited current therapies available. The designation underscores the importance of developing targeted therapeutics that address the underlying pathophysiology of rare diseases like XLH.

For more information about Anzor Pharmaceuticals, please visit www.anzorpharma.com.

About Anzor Pharmaceuticals

Anzor Pharmaceuticals is at the forefront of targeted fibroblast growth factor (FGF) therapies for cancer and metabolic disorders. The company's technology is based on proprietary FGF peptides and conjugates, with applications in obesity, chronic kidney disease, and skeletal disorders. Extensive research has demonstrated that FGF receptors are involved in several key pathways of disease.

Media Contact

Organization: Anzor Pharmaceuticals

Contact Person: Christopher Adams

Website: https://anzorpharma.com

Email: Send Email

Contact Number: +16179579858

Country:United States

Release id:31325

The post Anzor Pharmaceuticals Receives FDA Orphan Drug Designation for FGF23 Peptide Antagonist in Treatment of X-Linked Hypophosphatemia XLH appeared first on King Newswire. This content is provided by a third-party source.. King Newswire is a press release distribution agency. We do not accept any responsibility or liability for the accuracy, content, images, videos, licences, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section above.